BMRN
insider transactionsBIOMARIN PHARMACEUTICAL INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-3.3K
0 buy · 3.3K sell
Net value · 90d
-$176.7K
$0 in · $176.7K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
1
0 buy · 3.3K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
7.5K sh
Own +55%
-
Grant·A
Director
$0
7.5K sh
Own +77%
-
Grant·A
Director
$0
7.5K sh
Own +27%
-
Grant·A
Director
$0
7.5K sh
Own +18%
-
Grant·A
Director
$0
7.5K sh
Own +55%
-
Grant·A
Director
$0
7.5K sh
Own +19%
-
Grant·A
Director
$0
7.5K sh
Own +107%
-
Grant·A
Director
$0
7.5K sh
Own +55%
-
Grant·A
Director
$0
7.5K sh
Own +22%
-
Other·F
EVP, Chief Commercial Officer
$116.4K
2.3K sh · $50.20
Own -5%
-
Grant·A
Director
—
3.3K sh
Own +6%
-
Sell·S
EVP, Chief R&D Officer
$176.7K
3.3K sh · $53.85
Own -6%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 2, 2026 | Athena Countouriotis | Grant A | 7.5K | $0 |
| Jun 2, 2026 | Timothy P Walbert | Grant A | 7.5K | $0 |
| Jun 2, 2026 | Maykin Ho | Grant A | 7.5K | $0 |
| Jun 2, 2026 | Robert J. Hombach | Grant A | 7.5K | $0 |
| Jun 2, 2026 | Mark J Enyedy | Grant A | 7.5K | $0 |
| Jun 2, 2026 | Willard H Dere | Grant A | 7.5K | $0 |
| Jun 2, 2026 | Ian T Clark | Grant A | 7.5K | $0 |
| Jun 2, 2026 | Barbara W. Bodem | Grant A | 7.5K | $0 |
| Jun 2, 2026 | Elizabeth M Anderson | Grant A | 7.5K | $0 |
| May 20, 2026 | Cristin Hubbard | Other F | 2.3K | $116.4K |
| May 13, 2026 | Elizabeth M Anderson | Grant A | 3.3K | — |
| May 7, 2026 | Gregory R Friberg | Sell S | 3.3K | $176.7K |
About BMRN insider trading
This page tracks insider transactions for BIOMARIN PHARMACEUTICAL INC (BMRN) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.